Reassuring evidence does not link AstraZeneca shot to blood clots, English medical official says
Tweet
Share
E-mail
FILE PHOTO: Empty vials of Oxford/AstraZeneca's COVID-19 vaccine are pictured amid a vaccination campaign in Bierset, Belgium March 17, 2021. REUTERS/Yves Herman
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
LONDON (Reuters) - There is a lot of reassuring evidence that suggests there is no increased risk of blood clots from AstraZeneca's COVID-19 vaccine, England's deputy chief medical officer said, adding he expected the European Medicines Agency to agree.
"Behind the scenes, there is a lot of work going on to look at whether there is a signal in relation to what we call venous thrombo-embolic events - clots," Jonathan Van-Tam said at a news conference on Wednesday.
"And there's a lot of evidence emerging now that is reassuring that there is no overall excess signal or increased risk. And I expect, without prejudice to their absolute findings, those to be the final conclusions of the EMA and (Britain's) MHRA in due course."
(Reporting by Michael Holden, writing by Alistair Smout)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amazon's video game division cancels Lord of the Rings game announced in 2019
- Renault seeks to generate 1 billion euros from 'circular economy' by 2030
- South Africa regulator recommends lifting J&J vaccine pause after some conditions
Create E-mail Alert Related Categories
ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
